Fibrogen Inc (KYNB) — SEC Filings
Fibrogen Inc (KYNB) — 42 SEC filings. Latest: 10-Q (Nov 10, 2025). Includes 22 8-K, 9 SC 13G/A, 6 10-Q.
View Fibrogen Inc on SEC EDGAR
Overview
Fibrogen Inc (KYNB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: FIBROGEN INC (KYNB) reported a significant turnaround, posting a net income of $200.6 million for the three months ended September 30, 2025, compared to a net loss of $17.1 million in the same period of 2024. This dramatic shift was primarily driven by $213.8 million in income from discontinued oper
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 2 bearish, 38 neutral, 2 mixed. The dominant filing sentiment for Fibrogen Inc is neutral.
Filing Type Overview
Fibrogen Inc (KYNB) has filed 6 10-Q, 22 8-K, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of KYNB's 33 recent filings, 1 were flagged as high-risk, 22 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.1M |
| Net Income | $200.6M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $118.0M |
| Operating Margin | N/A |
| Total Assets | $137.0M |
| Total Debt | $119.5M |
Key Executives
- Dr. Elias V. Zerhouni
- Dr. K. Peter R. Nielsen
Industry Context
FibroGen operates in the highly competitive biopharmaceutical industry, focusing on developing treatments for serious unmet medical needs. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Recent trends include strategic divestitures to streamline operations and focus on core assets, as well as advancements in targeted therapies for conditions like cancer and blood disorders.
Top Tags
material-agreement (5) · pharmaceuticals (5) · 8-k (4) · filing (4) · Pharmaceuticals (3) · sec-filing (3) · corporate-governance (3) · financials (3) · executive-compensation (3) · FibroGen (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net income for Q3 2025 | $200.6M | Significant turnaround from a net loss of $17.1 million in Q3 2024, primarily due to discontinued operations. |
| Income from discontinued operations, net of tax, for Q3 2025 | $213.8M | Main driver of net income, stemming from the sale of China operations. |
| Total consideration from China operations sale | $220.4M | Comprised of $85.0 million enterprise value and $135.4 million net cash held in China. |
| Total revenue from continuing operations for Q3 2025 | $1.1M | Represents a very limited revenue stream post-divestiture, down from $26.5 million in Q3 2024 (before reclassification). |
| Research and development expenses for Q3 2025 | $1.2M | Dramatic decrease from $19.9 million in Q3 2024, reflecting strategic shift and divestiture. |
| Cash and cash equivalents as of September 30, 2025 | $118.0M | Increased from $50.5 million at December 31, 2024, due to divestiture proceeds. |
| Loss on debt extinguishments for nine months ended September 30, 2025 | $6.6M | Related to the repayment of senior secured term loan facilities. |
| Total stockholders' deficit attributable to FibroGen as of September 30, 2025 | $17.0M | Improved from $225.6 million at December 31, 2024, but still a deficit. |
| Common shares outstanding as of October 31, 2025 | 4,045,445 | Reflects the 1-for-25 reverse stock split effected on June 16, 2025. |
| Total liabilities as of September 30, 2025 | $119.5M | Significantly reduced from $398.2 million at December 31, 2024, post-divestiture. |
| Net Loss | $10.5M | Q2 2025 net loss, a significant improvement from $40.5M in Q2 2024 |
| Total Revenue | $20.0M | H1 2025 total revenue, a 20% decrease from $25.0M in H1 2024 |
| Drug Product Revenue (Astellas Japan) | $10.0M | H1 2025 revenue, down from $15.0M in H1 2024 |
| Drug Product Revenue (AstraZeneca US) | $10.0M | H1 2025 revenue, contributing to overall revenue |
| Revenue Decrease | 20% | Percentage decrease in total revenue from H1 2024 to H1 2025 |
Forward-Looking Statements
- {"claim":"FibroGen's stock price may experience downward pressure due to Vanguard's reduced stake.","entity":"FibroGen Inc","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"Other institutional investors might re-evaluate their positions in FibroGen following Vanguard's move.","entity":"Institutional Investors","targetDate":"Q2 2024","confidence":"low"}
- {"claim":"PRIMECAP Management Company will maintain a significant stake in FibroGen, Inc. throughout 2024.","entity":"PRIMECAP Management Company","targetDate":"December 31, 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Fibrogen Inc (KYNB)?
Fibrogen Inc has 42 recent SEC filings from Jan 2024 to Nov 2025, including 22 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KYNB filings?
Across 42 filings, the sentiment breakdown is: 2 bearish, 38 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Fibrogen Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Fibrogen Inc (KYNB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Fibrogen Inc?
Key financial highlights from Fibrogen Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KYNB?
The investment thesis for KYNB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Fibrogen Inc?
Key executives identified across Fibrogen Inc's filings include Dr. Elias V. Zerhouni, Dr. K. Peter R. Nielsen.
What are the main risk factors for Fibrogen Inc stock?
Of KYNB's 33 assessed filings, 1 were flagged high-risk, 22 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Fibrogen Inc?
Recent forward-looking statements from Fibrogen Inc include guidance on {"claim":"FibroGen's stock price may experience downward pressure due to Vanguard's reduced stake.","entity":"FibroGen I and 2 other predictions.